ORLANDO, Fla., Oct. 25 /PRNewswire/ -- GeneLink BioSciences, Inc. (OTC Bulletin Board: GNLK), a leading consumer genomics biotech company, today announced that it ranked number 62 on Technology Fast 500™, Deloitte's ranking of 500 of the fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. Rankings are based on percentage of fiscal year growth during the period from 2005-2009. GeneLink grew 2057 percent during this period. GeneLink ranked 17th overall in the Biotechnology/Pharmaceutical sector.
GeneLink's CEO Gary Beeman credits the Company's genetic science and its DNA-guided personalized health products for the dramatic revenue growth. "GeneLink's growth is a testament to the pioneering research by our scientists over the past decade as well as an indicator of the growing interest in personalized wellness products customized to each individual's DNA."
"GeneLink and the other 2010 Technology Fast 500™ winners forged ahead in a challenging economic environment to realize exceptional growth," said Phil Asmundson, vice chairman and Deloitte's U.S. technology, media and telecommunications leader. "Deloitte commends GeneLink for this impressive accomplishment."
"GeneLink has proven itself to be one of the fastest growing tech companies in North America, and we are proud to honor them as one of the 2010 Technology Fast 500™," said Mark Jensen, managing partner, Venture Capital Services, Deloitte & Touch LLP.
GeneLink previously ranked 92nd in the Deloitte "Fast 500" in 2008.
About GeneLink: GeneLink is a wellness company engaged in genetic test and product development. GeneLink's patented technologies include proprietary genetic assessments and products for personalized health, beauty and wellness. For information, visit www.genelinkbio.com.
This release contains certain forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in the press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement. GeneLink disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future developments or otherwise.
As used in this document, "Deloitte" means Deloitte LLP. Please see www.deloitte.com/us/about for a detailed description of the legal structure of Deloitte LLP and its subsidiaries.
SOURCE GeneLink BioSciences, Inc.